Sign in Subscribe
Clinical trials

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment

Strategic Insights

— 2 min read

The Attention Deficit Hyperactivity Disorder (ADHD) pipeline is bustling with activity, featuring 20+ companies and 22+ pipeline drugs in various stages of development. Supernus Pharmaceuticals Inc. recently announced a study to evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD. DelveInsight's report provides comprehensive insights into the ADHD pipeline landscape, including clinical and nonclinical stage products, and therapeutic assessment by product type, stage, route of administration, and molecule type.

Key Takeaways:

  • Supernus Pharmaceuticals Inc. is conducting a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD.
  • The leading ADHD companies are Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, and 3Z Pharmaceuticals.
  • Promising ADHD therapies include Centanafadine SR, Vyvanse (lisdexamfetamine dimesylate), NRP104, Lisdexamfetamine, Centanafadine Hydrochloride, Prospekta, and Amphetamine Sulfate.
  • DelveInsight's ADHD pipeline report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain.
  • The report highlights the unmet needs with respect to ADHD.
  • Cingulate Therapeutics is developing CTx-1301, which utilizes their Precision Timed Release (PTR) drug delivery platform technology to create a breakthrough multi-core formulation of dexmethylphenidate.
  • Otsuka Pharmaceutical is developing Centanafadine, a serotonin-norepinephrine-dopamine, triple-reuptake inhibitor, which has demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both investigational studies.
  • MindMed is developing MM120, a tartrate salt form of lysergide, which is being evaluated in the Phase II stage of its development for the treatment of Attention-Deficit Hyperactivity Disorder.

Statistics:

  • There are 20+ companies and 22+ pipeline drugs in the ADHD pipeline landscape.
  • The ADHD pipeline report includes 900 adult patients from age 18 to 55 years old, and diagnosed with ADHD, who were randomized in the two phase III studies of Centanafadine.
  • The studies were randomized, double-blind, multicenter, and placebo-controlled with parallel groups.
  • Approximately 7 percent of patients reported adverse events in the combined analysis of tolerability across the two studies.
  • CTx-1301 is being evaluated in the Phase III stage of its development for the treatment of Attention-Deficit Hyperactivity Disorder.
  • MM120 is being evaluated in the Phase II stage of its development for the treatment of Attention-Deficit Hyperactivity Disorder.

Sources:

  • M2 PRESSWIRE-October 20, 2025-: Attention Deficit Hyperactivity Disorder Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight
  • DelveInsight's "Attention Deficit Hyperactivity Disorder Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Attention Deficit Hyperactivity Disorder pipeline landscape.
  • M2 COMMUNICATIONS RDATE:17102025
  • DelveInsight's "Attention Deficit Hyperactivity Disorder Pipeline Insight 2025" report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain.

Read more